Registration TrialLantus® + OADs vs NPH + OADs in Patients With Type 2 diabetes2,3
In a 52-week study, 570 patients with type 2 diabetes poorly controlled by OADs were randomized to either Lantus® (n=289) or NPH (n=281) at bedtime to reach a target FPG of <120 mg/dL. OADs were continued. Initial insulin dose and titration schedule was left to the discretion of the individual investigators. Primary endpoint was change in A1C.2,3
An appropriate dose and proper titration helped many patients achieve glycemic targets.
Data from a 24-week, multicenter, randomized, parallel, open-label trial of 756 overweight men and women compared the abilities and associated hypoglycemic effects of Lantus® added to prestudy OADs (n=367) vs NPH added to prestudy OADs (n=389) in insulin-naïve patients with type 2 diabetes and inadequate glycemic control (A1C >7.5%) on 1 or 2 oral agents (sulfonylureas, metformin, or thiazolidinediones) and treated to a target FPG ≤100 mg/dL. Lantus® or NPH was administered once daily at bedtime. Primary endpoint was percentage of patients achieving A1C ≤7.0% without a single instance of symptomatic nocturnal hypoglycemia.
See how Lantus® provides effective, improved glycemic control in diabetes patients.†
†Lantus® Prescribing Information. August 2015.
Lantus® is a once-daily, long-acting insulin.**
**Lantus® Prescribing Information. August 2015.
Lantus® is a basal insulin with demonstrated long-term CV safety data††